For years, Semaglutide (a GLP-1 receptor agonist) redefined the treatment of obesity and Type 2 Diabetes. But then came Tirzepatide—a groundbreaking "dual agonist" that pushed the boundaries even further. For researchers, understanding the key differences between these two powerful peptides is crucial.
This post delves into how each molecule works, their clinical efficacy, and why…